Detailed Narrative
Q1 FY26 Performance Overview
Godavari Biorefineries Ltd reported a revenue from operations of INR533.2 crores in Q1 FY26, showing a year-on-year improvement from INR522.5 crores in Q1 FY25. The company achieved a positive EBITDA of INR6.5 crores, marking a significant turnaround from a loss in the same period last year, with an improvement of INR16 crores. Despite this, PBT remained negative at INR22.3 crores, though it improved by INR19 crores from a loss of INR41.6 crores in Q1 FY25. Gross margin expanded by 512 basis points year-on-year to 19%, driven by product mix and pricing discipline. Interest costs decreased by 22% year-on-year to INR15 crores due to debt reduction efforts.
Strategic Shift to Bio-based Chemicals
The bio-based chemical segment is a strategic pivot for the company, registering a robust 43% increase in EBITDA during Q1 FY26. This growth is supported by customer commitment to green chemistry and the development of high-value specialty chemicals. The company aims for an EBITDA to sales margin in excess of 15% for bio-based specialty chemicals by FY29. Ongoing de-bottlenecking and process optimization are expected to further enhance this segment's capacity and profitability.
Ethanol Expansion and Energy Transition
Ethanol is a key growth area, aligned with the Indian government's energy security and green energy transition goals, including the 20% ethanol blending target already achieved. The company's upcoming 200 kilo liters per day fungible grain maize distillery is progressing ahead of schedule, with commercial production expected by the end of calendar year 2025. This new facility is projected to contribute over INR400 crores in annual revenue, based on current ethanol prices and 300 days of operation, and will strengthen multi-feedstock capabilities, reducing seasonality.
Drug Discovery Initiatives
Godavari Biorefineries is making significant strides in drug discovery. A novel anti-cancer molecule has received European patent validation, and safety trials concluded without dose-limiting toxicity. Additionally, a Chinese patent was secured for another promising anti-cancer compound. The next step involves applying to the CDSCO for preliminary efficacy trials, with the out-licensing process to pharmaceutical companies expected to take two to three years after successful trials.
Capital Expenditure and Funding
To achieve its strategic goals, including the 3x EBITDA margin target by FY29, the company plans a further investment of INR325 crores. This investment will be allocated approximately 70% to the bio-based specialty chemicals side and 30% to ethanol capacity expansion. The company is exploring various fundraising means with its board to support this financing plan. The new grain distillery is expected to start contributing EBITDA from Q4 FY26, with major impacts on the 3x EBITDA target reflecting from FY27-FY29.
Future Outlook and Segment Contribution
The company anticipates stronger ethanol performance from FY26 onwards and improvement in chemicals in FY26, with greater change from FY27. Going forward⏳, ethanol and chemical businesses are each expected to contribute 40-45% to revenue, while the sugar and co-generation segment is projected to remain flat. This shift in mix, coupled with the new grain-based ethanol and annual chemical businesses, is expected to reduce the overall seasonality of the company's profitability.